A groundbreaking assay for detecting acute myeloid leukemia (AML) through KMT2A gene fusions guarantees to boost analysis and remedy, representing a serious leap in leukemia analysis.
Researchers report that enhancing the accuracy of detecting a selected molecular marker in leukemic cells can considerably enhance the evaluation of measurable residual illness. This development can result in better-informed remedy selections, finally enhancing affected person outcomes.
A novel assay that detects a singular molecular marker in sufferers with acute myeloid leukemia (AML) might revolutionize the way in which this illness is detected and handled in response to a new report not too long ago revealed in The Journal of Molecular Diagnostics revealed by Elsevier. This assay might enhance the detection of AML pushed by KMT2A gene fusions and will influence remedy decision-making, assessing response to remedy, and long-term surveillance.
AML is a uncommon, aggressive blood most cancers recognized in round 120,000 people worldwide annually. Detecting residual illness throughout remedy is important for figuring out prognosis and guiding remedy selections. Presently, the strategies for detecting measurable residual illness (MRD) throughout remedy for AML embody bone marrow morphology, multiparameter circulate cytometry (MPFC), and DNA sequencing.
Morphologic evaluation solely detects leukemic cells at a 5% restrict of detection. MPFC has a extra delicate restrict of detection at 0.01% to 0.001%, however is difficult to implement and interpret, and isn’t standardized between laboratories. DNA sequencing approaches can establish leukemic cells by their somatic mutation profile however are costly and might be confounded by clonal hematopoiesis in non-leukemic blood cells.
A Leap Ahead in Leukemia Analysis
Lead investigator Grant A. Challen, Ph.D., Division of Oncology, Division of Drugs, Washington College Faculty of Drugs in St. Louis, explains, “Oncogenic fusions are sometimes disease-defining and current a singular marker of leukemic cells that aren’t normally current in wholesome cells. Different ailments equivalent to power myeloid leukemia (CML) can already be tracked by the canonical BCR-ABL fusion and sensitively detecting these fusions has revolutionized how CML is handled. For AML sufferers with oncogenic fusions driving their illness, the KMT2A fusion is a molecular marker that may be leveraged for delicate MRD detection. We subsequently wished to develop a platform for delicate KMT2A fusion-detection to enhance how we detect and deal with this illness.”
Investigators developed a novel droplet digital PCR assay enabling delicate KMT2A fusion detection with the 5 most typical fusion companions. There are not less than 80 identified KMT2A fusion companions, however about 80% of fusions contain simply 5 companions — AF9, AF6, AF4, ELL, and ENL. They benchmarked the assay in human cell traces and affected person samples to reveal delicate and particular KMT2A fusion detection.
The assay detects these fusions by partitioning cDNA molecules into microfluidic droplets which might be assayed with primers and probes that solely produce a optimistic sign when fusion transcripts are current. Investigators had been in a position to mix a number of primer/probe units focusing on completely different fusions right into a pooled fusion detection reagent. Additionally they confirmed the detection of KMT2A fusions in affected person samples identified to harbor KMT2A fusions.
Implications for AML Therapy and Future Analysis
Dr. Challen notes, “We present that the assay doesn’t produce false-positive indicators in samples from wholesome people. The assay is definitely expanded to incorporate extra oncogenic fusions. This has a possible influence on remedy decision-making and assessing response to remedy. Figuring out whether or not a remedy is working or not is critically vital for selections concerning when to escalate remedy or pursue hematopoietic stem cell transplant.”
He concludes, “It is a sturdy new device for delicate KMT2A fusion detection that’s instantly relevant for illness detection in sufferers with leukemia pushed by these fusions. It fills a void for oncogenic fusion detection and gives some technical enhancements. The assay can also be scalable—extra fusions might be simply added to the assay—to increase protection for different oncogenic fusions. We’re enhancing blood most cancers detection one drop at a time!”
Reference: “Droplet Digital PCR for Oncogenic KMT2A Fusion Detection” by Andrew L. Younger, Hannah C. Davis and Grant A. Challen, 7 October 2023, The Journal of Molecular Diagnostics.
DOI: 10.1016/j.jmoldx.2023.09.006
The research was funded by the Nationwide Institutes of Well being and the Leukemia and Lymphoma Society.
